Source comparison
Comparison: Growth Hormone Secretagogues for Strength Research
CJC-1295 (DAC) GHRH receptor agonist with albumin binding 60–100 mcg/kg weekly SC 6–8 days sustained Highly selective for GH, no prolactin/cortisol stimulation No. Long half-life prevents need for cycling Best for researchers prioritizing stable IGF-1 elevatio
This comparison does not assign a generated winner or score.
- CJC-1295 (DAC)
- GHRH receptor agonist with albumin binding
- 60–100 mcg/kg weekly SC
- 6–8 days sustained
- Highly selective for GH, no prolactin/cortisol stimulation
- No. Long half-life prevents need for cycling
- Best for researchers prioritizing stable IGF-1 elevation without frequent dosing; minimal side effect profile
- Ipamorelin
- Ghrelin receptor (GHS-R1a) agonist
- 200–300 mcg per dose, 1–3× daily
- 2–3 hours pulsatile
- GH-selective; does not elevate cortisol or prolactin
- No. Maintains efficacy with continuous use
- Ideal for protocols requiring precise GH pulse timing around training or sleep; well-tolerated long-term
- Hexarelin
- Potent ghrelin analog
- 100–200 mcg 2× daily
- 60–90 minutes peak
- Non-selective; some cortisol elevation; direct cardiac effects
- Yes. 2 weeks on, 2 weeks off to prevent desensitization
- Most potent acute GH response; best for short-term studies or cycled protocols; requires tolerance monitoring
- GHRP-6
- First-generation ghrelin mimetic
- 100–200 mcg 2–3× daily
- 2–3 hours
- Non-selective; significant appetite stimulation
- Mild. Efficacy maintained but appetite side effects may limit use
- Outdated compared to Ipamorelin; still used in appetite-focused research but inferior selectivity profile